Yeonjoo Choi, MD from The Catholic University of Korea Incheon St. Mary’s Hospital speaks about T-cell Agonists In Cancer Immunotherapy.
Link to Article:
https://jitc.bmj.com/content/8/2/e000966
Article:
Cancer cells have the ability to avoid the body’s immune system. Immune checkpoint drugs, on the other hand, can stop this evasion and boost T cell antitumor activity. Targeting costimulatory molecules expressed on the surface of T cells, such as 4-1BB, OX40, inducible T-cell costimulator, and glucocorticoid-induced tumor necrosis factor receptor, are further methods for boosting antitumor T-cell activity. CD40 also targets the regulation of antigen-presenting cell activation, which eventually leads to T-cell activation. These costimulatory molecule antagonists have shown promise in preclinical and early-phase studies, and are currently being evaluated in clinical trials. In addition, in patients with advanced malignancies, researchers are testing combinations of immune modulators with checkpoint inhibition, radiation, and cytotoxic chemotherapeutic medicines. Based on their usage in recent and continuing clinical studies, this review provides a complete overview of the current understanding of T-cell agonists.